Intellia Therapeutics (NTLA) Misses Q4 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
February 27, 2020 7:30 AM ESTOn track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to dose first patients in 2H 2020Plans to submit an IND application for NTLA-5001, a WT1-directed TCR-T cell therapy, for the treatment of acute myeloid leukemia in 1H 2021Expects to nominate a development candidate for the treatment of hereditary angioedema in 1H 2020Ends 2019 with a strong cash position of $284 million; cash runway through YE 2021
CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:... More
